Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
Acute therapies continue to report strong growth compared to chronic ones.
This is the first time in South Asia an indigenously made drone was used to transport Covid-19 vaccines
Subscribe To Our Newsletter & Stay Updated
